date:May 23, 2014
nt to Evolva. Evolva is eligible for total milestone payments of up to US$7.5 million during the RD period.
In 2013, Cargill and Evolva entered into an agreement to jointly develop and commercialise fermentation-based minor steviol glycosides. Later in 2013 the companies announced that their program was moving into pilot-scale ahead of schedule.
We are encouraged by this projects trajectory, said David Henstrom, global business director for Health Ingredients, Cargill. We look forward to offer